A phase II study of dose-dense epirubicin plus cyclophosphamide followed by docetaxel plus capecitabine and pegfilgrastim support as preoperative therapy for patients with stage II, IIIA breast cancer

Annals of Oncology

Volumn 18, Issue 6, 2007, Pages 1015-1020

  Natoli, C ^a   Cianchetti, E ^a   Tinari, N ^a   Angelucci, D ^a   Grassadonia, A ^a   Zilli, M ^a   Ficorella, C ^b   Ricevuto, E ^b   Grossi, S ^a   De Tursi, M ^a   Carella, C ^a   Rispoli, A I ^b   Iacobelli, S ^a  

^a UNIVERSITY OF CHIETI   (Italy)

^b UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

Breast cancer; Dose dense chemotherapy; Pathologic complete response; Preoperative chemotherapy

Indexed keywords

CAPECITABINE; CYCLOPHOSPHAMIDE; DIPHENHYDRAMINE; DOCETAXEL; EPIRUBICIN; ERYTHROPOIETIN; HORMONE; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ANEMIA; ARTICLE; AXILLARY LYMPH NODE; BLOOD TOXICITY; BREAST CANCER; BREAST SURGERY; CANCER INVASION; CANCER STAGING; CARCINOMA IN SITU; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HAND FOOT SYNDROME; HUMAN; INCIDENCE; LEUKOPENIA; MALE; MUCOSA INFLAMMATION; NAIL DISEASE; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PREOPERATIVE CARE; PRIORITY JOURNAL; SIDE EFFECT; THROMBOCYTOPENIA; VOMITING;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; DRUG ADMINISTRATION SCHEDULE; FEMALE; FILGRASTIM; HUMANS; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; POSTMENOPAUSE; PREMENOPAUSE; PREOPERATIVE CARE; TAXOIDS;

EID: 34447344835     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm076     Document Type: Article

References (44)

1. Hortobagyi GN. Comprehensive management of locally advanced breast cancer. Cancer 1990; 66: 1387-1391.
2. Bear HD. Indications for neoadjuvant chemotherapy for breast cancer. Semin Oncol 1998; 25: 3-12.
3. Kaufmann M, Hortobagyi GN, Godhirsch S. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: An update. J Clin Oncol 2006; 24: 1940-1949.
4. Fisher B, Bryant J, Wolmark N et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998; 16: 2672-2685.
5. Wolff AC, Davidson NE. Primary systemic therapy in operable breast cancer. J Clin Oncol 2000; 18: 1558-1569.
6. Mauri D, Pavlidis N, Ioannidis JP. Neoadjuvant versus adjuvant systemic treatment in breast cancer: A meta-analysis. J Natl Cancer Inst 2005; 97: 188-194.
7. Kuerer HM, Newman LA, Smith TL et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph nodes response to doxorubicin-based chemotherapy. J Clin Oncol 1999; 17: 460-469.
8. Smith IC, Heys SD, Hutcheon AW et al. Neoadjuvant chemotherapy in breast cancer: Significantly enhanced response with docetaxel. J Clin Oncol 2002; 20: 1456-1466.
9. Mauriac L, MacGrogan G, Avril A et al. Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm. A unicentre randomised trial with a 124-month median follow-up. Institut Bergoni Bordeaux Groupe Sein (IBBGS). Ann Oncol 1999; 10: 47-52.
10. Von Minckwitz G, Costa SD, Raab G et al. Dose-dense doxorubicin, docetaxel, and granulocyte colony-stimilating factor support with or without tamoxifen as preoperative therapy in patients with operable carcinoma of the breast: A randomized, controlled, open phase IIb study. J Clin Oncol 2001; 19: 3506-3515.
11. Heys SD, Hutcheon AW, Sarkar TK et al. Aberdeen Breast Group: neoadjuvant docetaxel in breast cancer: 3-year survival results from the Aberdeen trial. Clin Breast Cancer 2002; 2: S69-S74.
12. Bear HD, Anderson S, Brown A et al. National Surgical Adjuvant Breast and Bowel Project B-27: The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: Preliminary results from National Surgical Adjuvant Breast and Bowel Project B-27. J Clin Oncol 2003; 21: 4165-4174.
13. O'Shaughnessy J. Capecitabine and docetaxel in advanced breast cancer: analyses of a phase III comparative trial. Oncology (Huntingt) 2002; 16: 17-22.
14. Miwa M, Ura M, Nishida M et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumors by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998; 34: 1274-1281.
15. Sawada N, Ishikawa T, Fukase Y et al. Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/ taxotere in human cancer xenografts. Clin Cancer Res 1998; 4: 1013-1019.
16. Kurosumi M, Tabei T, Suemasu K et al. Enhancement of immunohistochemical reactivity for thymidine phosphorilase in breast carcinoma cells after administration of docetaxel as a neoadjuvant chemotherapy in advanced breast cancer patients. Oncol Rep 2000; 7: 945-948.
17. Grem JL, Nguyen D, Monahan BP et al. Sequence-dependent antagonism between fluorouracil and paclitaxel in human breast cancer cells. Biochem Pharmacol 1999; 58: 477-486.
18. Wardley A. Capecitabine: Expanding options for the treatment of patients with early or locally advanced breast cancer. Oncologist 2006; 11: 20-26.
19. Citron ML, Berry DA, Cirrincione C et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003; 21: 1431-1439.
20. Norton L. Evolving concepts in the systemic drug therapy of breast cancer. Semin Oncol 1997; 24 (Suppl 10): S3-S10.
21. Norton L. A gompertzian model of human breast cancer growth. Cancer Res 1998; 48: 7067-7071.
22. Gianni AM, Piccart MJ. Optimizing chemotherapy dose density and dose intensity: New strategies to improve outcomes in adjuvant therapy for breast cancer. Eur J Cancer 2000; 36: S1-S3.
23. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: Experience from a large study with long-term follow-up. Histopathology 1991; 19: 403-410.
24. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92: 205-216.
25. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989; 10: 1-10.
26. Early Breast Cancer Trialist's Collaborative Group. Polichemotherapy for early breast cancer: An overview of the randomised trials. Lancet 1998; 352: 930-942.
27. Steger GG, Wenzel C, Schmidinger M et al. Predictive factors for a complete pathologic response (pCR) in primary breast cancer treated neoadjuvantly with a epirubicin/taxane + G-CSF regimen. Proc Am Soc Clin Oncol 2001; 20: 39a (Abstr 154).
28. Gianni L, Baselga J, Eiermann W et al. First report of the European Cooperative Trial in operable breast cancer (ECTO): Effects of primary systemic therapy (PST)on local-regional disease. Proc Am Soc Clin Oncol 2002; 21: 34a (Abstr 132).
29. Thames HD, Bucholtz IA, Smith CD. Frequency of first metastatic events in breast cancer: Implications for sequencing of systemic and loco-regional treatment. J Clin Oncol 1999; 17: 2649-2658.
30. Bonadonna G, Valagussa P. Primary chemotherapy in operable breast cancer. Semin Oncol 1996; 23(4): 464-474.
31. Fisher B, Brown A, Mamounas E et al. Effect of preoperative chemotherapy on local-regional disease women with operable breast cancer: Finding from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 1997; 15: 2483-2493.
32. Delgado GL, Nader LA, Brondi LG et al. Neoadjuvant (high-dose doxorubicin) plus adjuvant CMF chemotherapy for stages II e IIIA breast cancer: A phase II study. Proc Am Soc Clin Oncol 2000; 19: 133a (Abstr 521).
33. von Minckwitz G, Costa SD, Eiermann W et al. Maximized reduction of primary breast tumor size using preoperative chemotherapy with doxorubicin and docetaxel. J Clin Oncol 1999; 17: 1999-2005.
34. Miller KD, McSkill-Stevens W, Sisk J et al. Combination versus sequential doxorubicin and docetaxel as primary chemotherapy for breast cancer: A randomised pilot trial of the Hoosier Oncology Group. J Clin Oncol 1999; 17: 3033-3037.
35. Valero V, Esteva FJ, Sahin AA et al. Phase II trial of neoadjuvant chemotherapy with docetaxel and doxorubicin, surgery, adjuvant CMF, and radiotherapy +/- tamoxifen in locally advanced breast cancer. Breast Cancer Res Treat 2000; 64: 69 (Abstr 253).
36. Tubiana-Hulin M, Dieras V, Fumoleau P et al. Phase II combining docetaxel and doxorubicin in the neoadjuvant setting in patients with operable breast carcinoma: Final results. Breast Cancer Res Treat 2000; 64: 69 (Abstr 250).
37. von Minckwitz G, Costa SD, Raab G et al. Dose-dense doxorubicin, docetaxel, and granulocyte colony-stimulating factor support with or without tamoxifen as preoperative therapy in patients with operable carcinoma of the breast: A randomised, controlled open phase IIb study. J Clin Oncol 2001; 19: 3506-3515.
38. Untch M, Konecny G, Ditsch N et al. Dose-dense sequential epirubicin-paclitaxel as preoperative treatment of breast cancer: results of a randomized AGO study. Proc Am Soc Clin Oncol 2002; 21: 133a (Abstr 133).
39. von Minckwitz G, Raab G, Caputo A et al. Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: The GEPARDUO study of the German Breast Group. J Clin Oncol 2005; 23: 2676-2685.
40. Green MC, Budzar AU, Smith T et al. Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J Clin Oncol 2005; 23: 5983-5992.
41. Chevallier B, Roche H, Olivier JP et al. Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate. Am J Clin Oncol 1993; 16: 223-228.
42. Sataloff D, Mason B, Prestipino A et al. Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: A determinant of outcome. J Am Coll Surg 1995; 180: 297-306.
43. Honkoop AH, van Diest PJ, de Jong JS et al. Prognostic role of clinical, pathological and biological characteristics in patients with locally advanced breast cancer. Br J Cancer 1998; 77: 621-626.
44. Buzdar AU, Ibrahim NK, Francis D et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: Results of a randomised trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 2005; 23: 3676-3685.